Cartesian Therapeutics Inc (NAS:RNAC)
$ 35.86 1.28 (3.69%) Market Cap: 638.17 Mil Enterprise Value: 519.22 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Selecta Biosciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript

Oct 27, 2021 / 03:00PM GMT
Release Date Price: $108 (-4.00%)
Maury Raycroft
Jefferies Financial Group Inc. - Analyst

Hi, everyone. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Carsten Brunn, the CEO of Selecta Biosciences. Thanks for joining us today, Carsten.

Carsten Brunn
Selecta Biosciences, Inc. - President & CEO

Thanks for having me, Maury. I'll be making forward-looking statements so please take notice. So just want to start giving a bit of an overview. So Selecta is an immune tolerance platform company. Our technology is called ImmTOR, which is a biodegradable nanoparticle that encapsulates the immunomodulator rapamycin, and what it does is it induces antigen-specific immune tolerance. We have several applications. I really want to focus on gene therapy in this talk, but I want to touch at least on the others as we have pretty significant clinical data and advanced assets in Phase 3.

So there's three pillars to the pipeline. The first, we use ImmTOR to redose highly immunogenic enzymes. The indication here is chronic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot